MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition
Item 7.01Regulation FD Disclosure
On November 30, 2017, MiMedx Group, Inc. issued a press release announcing its expectations for revenues for the period ended December 31, 2017. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.
Item 9.01Financial Statements and Exhibits
(d)Exhibits
MIMEDX GROUP, INC. ExhibitEX-99.1 2 a113020178-kexhibitpressre.htm PRESS RELEASE Exhibit Exhibit 99.1 PRESS RELEASE Contact: Michael SenkenPhone: (770) 651-9100MiMEdx Announces Expectation To Exceed Top End of FOURTH QUARTER Revenue Guidance Of $88 Million Marietta,…To view the full exhibit click here
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.
